Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Panel Raises No Objection to Public Coverage of Shingles Vaccines
June 21, 2024
- SanBio’s Lead Cell Therapy in Line for Conditional Nod but Can’t Be Shipped Until Comparability Is Confirmed
June 20, 2024
- Xevinapant Earns Sakigake Tag, 6 APIs Get Orphan Status
June 20, 2024
- Opposition Party Urges Health Minister to Scrap Off-Year Drug Price Revision
June 19, 2024
- MHLW to Bankroll Up to 50 Billion Yen Each to KM, Daiichi for Vaccine Trials
June 19, 2024
- Nitrosamine Risk Communication Guidance Issued, Effective Immediately
June 19, 2024
- LDP Tweaks Honebuto Text on Off-Year Revision, Waters Down Push for CEA Expansion
June 18, 2024
- ICH Agrees to Draft Nitrosamine Guideline, Aims to Set Acceptable Intakes
June 18, 2024
- PMDA Chief Strenuously Delivering Info on Japan Regulations at Overseas Confabs
June 17, 2024
- First Generics Joining NHI Price List in June Hits Record Low, Bridion is Only Target
June 14, 2024
- MHLW Proposes Supply Info System for All Prescription Drugs, FY2027 Launch Eyed
June 14, 2024
- SanBio’s Lead Cell Therapy Up for Review Again on June 19
June 14, 2024
- Tezspire Braced for CEA Price Cut, AstraZeneca's Appeal Dismissed
June 13, 2024
- LDP Members Urge Modification of Honebuto Draft to Push Rethink of Off-Year Drug Price Cuts
June 13, 2024
- Social Security Budget Ceiling Looks Set to Continue 3 More Years: Honebuto Draft
June 12, 2024
- Honebuto Draft Equivocal on Off-Year Price Cuts, but Focuses on FY2025 Revision
June 12, 2024
- Label Revisions Ordered for Brimonidine, Finerenone, and More
June 12, 2024
- MHLW to Issue Nitrosamine Risk Communication Guidance by June-End; Draft Now Ready
June 11, 2024
- Govt’s New Capitalism Council Proposes Extending Scope of Mixed-Billing Scheme
June 11, 2024
- Japan Enacts Bill to Amend Regenerative Medicine Safety Act, Clinical Trial Act
June 11, 2024
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…